A clinical-stage immunology company targeting infectious diseases is planning a public listing this week.
San Francisco, California-based Vir Biotechnology, Inc. is seeking to offer 7.143 million shares in an IPO, with the shares expected to be priced between…
$20 and $22 apiece, the S-1/A filing revealed.
At the midpoint of the estimated price range, the offering is expected to raise about $150 million.
The company has applied for listing its shares on the Nasdaq under the ticker symbol “VIR.”
Goldman Sachs, JP Morgan, Cowen and Barclays are the underwriters for the offering.
Vir, founded in 2016, is a clinical-stage immunology company, which used a combination of immunologic insights and cutting-edge technology to treat and prevent serious infectious diseases.
Infectious diseases cause hundreds of billions of dollars of economic burden each year, according to the company.
Vir has four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid or siRNA.
Its product pipeline consists of candidates targeting hepatitis B virus, influenza A, HIV, and tuberculosis.
Source: S-1 filing
Vir expects to use the net proceeds from the offering to fund R&D of its product candidates, including VIR-2218, VIR-3434, VIR-2482.
Vir reported revenues of…
Continue reading at BENZINGA.com